Drug Type Small molecule drug |
Synonyms R-etodolac, RAK-593, SDX 101 + [1] |
Target |
Mechanism CTNNB1 inhibitors(Catenin beta 1 inhibitors), NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC17H21NO3 |
InChIKeyNNYBQONXHNTVIJ-QGZVFWFLSA-N |
CAS Registry87226-41-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | (R)-Etodolac | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 2 | FR | 01 Sep 2004 | |
Chronic Lymphocytic Leukemia | Phase 2 | DE | 01 Sep 2004 | |
Chronic Lymphocytic Leukemia | Phase 2 | PL | 01 Sep 2004 | |
Chronic Lymphocytic Leukemia | Phase 2 | SE | 01 Sep 2004 | |
Chronic Lymphocytic Leukemia | Phase 2 | GB | 01 Sep 2004 | |
Multiple Myeloma | Phase 2 | US | 01 Feb 2002 | |
Prostatic Cancer | Preclinical | US | - |